One-week esomeprazole treatment: An effective confirmatory test in patients with suspected gastroesophageal reflux disease

Folke Johnsson, J. G. Hatlebakk, A. C. Klintenberg, J. Román, E. Tóth, A. Stubberöd, A. Falk, R. Edin

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Background: Symptomatic response to acid inhibition can be used as a guide in diagnosing patients with reflux symptoms. The proton-pump inhibitor (PPI) omeprazole has been used as such a diagnostic tool. Intragastric acid control with esomeprazole is more effective than other PPIs and has the potential to offer an advance in the diagnostic use of PPIs. Methods: Patients experiencing heartburn (for ≥6 months) were studied in this randomized, double-blind, multicenter study. Following a 3-day placebo run-in, 440 patients were randomized to 14 days' treatment with esomeprazole 40 mg once daily (o.d.), esomeprazole 20 mg twice daily (b.i.d.) or placebo. Heartburn symptoms were recorded daily. Endoscopy and 24-h esophageal pH-monitoring were performed to determine the presence of gastroesophageal reflux disease (GERD). The esomeprazole treatment test was considered positive if patients' symptoms improved during the treatment period compared with symptoms recorded on Day 0. Results: 63 patients were excluded from the analysis due to lack of symptoms on Day 0 or failure to complete pH-monitoring. The sensitivity of an esomeprazole treatment test in confirming GERD increased during the first days of treatment and stabilized between 79% and 86% after 5 days (both esomeprazole arms). The corresponding figure for the placebo arm was 36%. Specificity was variable (24%-65%) for both active treatment and placebo. Conclusion: A treatment test with esomeprazole 40 mg has a high sensitivity in confirming GERD. Furthermore, the data indicate that 1-week treatment with a once-daily dosage is sufficient to ensure adequate diagnosis.

Original languageEnglish
Pages (from-to)354-359
Number of pages6
JournalScandinavian Journal of Gastroenterology
Volume38
Issue number4
DOIs
Publication statusPublished - Apr 1 2003

Fingerprint

Esomeprazole
Gastroesophageal Reflux
Placebos
Heartburn
Therapeutics
Esophageal pH Monitoring
Acids
Omeprazole
Proton Pump Inhibitors
Double-Blind Method
Endoscopy
Multicenter Studies

Keywords

  • Diagnostic
  • Esomeprazole
  • Gastroesophageal reflux disease
  • Sensitivity

ASJC Scopus subject areas

  • Gastroenterology

Cite this

One-week esomeprazole treatment : An effective confirmatory test in patients with suspected gastroesophageal reflux disease. / Johnsson, Folke; Hatlebakk, J. G.; Klintenberg, A. C.; Román, J.; Tóth, E.; Stubberöd, A.; Falk, A.; Edin, R.

In: Scandinavian Journal of Gastroenterology, Vol. 38, No. 4, 01.04.2003, p. 354-359.

Research output: Contribution to journalArticle

Johnsson, Folke ; Hatlebakk, J. G. ; Klintenberg, A. C. ; Román, J. ; Tóth, E. ; Stubberöd, A. ; Falk, A. ; Edin, R. / One-week esomeprazole treatment : An effective confirmatory test in patients with suspected gastroesophageal reflux disease. In: Scandinavian Journal of Gastroenterology. 2003 ; Vol. 38, No. 4. pp. 354-359.
@article{0dff909334af437d85a81dc034c686ca,
title = "One-week esomeprazole treatment: An effective confirmatory test in patients with suspected gastroesophageal reflux disease",
abstract = "Background: Symptomatic response to acid inhibition can be used as a guide in diagnosing patients with reflux symptoms. The proton-pump inhibitor (PPI) omeprazole has been used as such a diagnostic tool. Intragastric acid control with esomeprazole is more effective than other PPIs and has the potential to offer an advance in the diagnostic use of PPIs. Methods: Patients experiencing heartburn (for ≥6 months) were studied in this randomized, double-blind, multicenter study. Following a 3-day placebo run-in, 440 patients were randomized to 14 days' treatment with esomeprazole 40 mg once daily (o.d.), esomeprazole 20 mg twice daily (b.i.d.) or placebo. Heartburn symptoms were recorded daily. Endoscopy and 24-h esophageal pH-monitoring were performed to determine the presence of gastroesophageal reflux disease (GERD). The esomeprazole treatment test was considered positive if patients' symptoms improved during the treatment period compared with symptoms recorded on Day 0. Results: 63 patients were excluded from the analysis due to lack of symptoms on Day 0 or failure to complete pH-monitoring. The sensitivity of an esomeprazole treatment test in confirming GERD increased during the first days of treatment and stabilized between 79{\%} and 86{\%} after 5 days (both esomeprazole arms). The corresponding figure for the placebo arm was 36{\%}. Specificity was variable (24{\%}-65{\%}) for both active treatment and placebo. Conclusion: A treatment test with esomeprazole 40 mg has a high sensitivity in confirming GERD. Furthermore, the data indicate that 1-week treatment with a once-daily dosage is sufficient to ensure adequate diagnosis.",
keywords = "Diagnostic, Esomeprazole, Gastroesophageal reflux disease, Sensitivity",
author = "Folke Johnsson and Hatlebakk, {J. G.} and Klintenberg, {A. C.} and J. Rom{\'a}n and E. T{\'o}th and A. Stubber{\"o}d and A. Falk and R. Edin",
year = "2003",
month = "4",
day = "1",
doi = "10.1080/00365520310002139",
language = "English",
volume = "38",
pages = "354--359",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - One-week esomeprazole treatment

T2 - An effective confirmatory test in patients with suspected gastroesophageal reflux disease

AU - Johnsson, Folke

AU - Hatlebakk, J. G.

AU - Klintenberg, A. C.

AU - Román, J.

AU - Tóth, E.

AU - Stubberöd, A.

AU - Falk, A.

AU - Edin, R.

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Background: Symptomatic response to acid inhibition can be used as a guide in diagnosing patients with reflux symptoms. The proton-pump inhibitor (PPI) omeprazole has been used as such a diagnostic tool. Intragastric acid control with esomeprazole is more effective than other PPIs and has the potential to offer an advance in the diagnostic use of PPIs. Methods: Patients experiencing heartburn (for ≥6 months) were studied in this randomized, double-blind, multicenter study. Following a 3-day placebo run-in, 440 patients were randomized to 14 days' treatment with esomeprazole 40 mg once daily (o.d.), esomeprazole 20 mg twice daily (b.i.d.) or placebo. Heartburn symptoms were recorded daily. Endoscopy and 24-h esophageal pH-monitoring were performed to determine the presence of gastroesophageal reflux disease (GERD). The esomeprazole treatment test was considered positive if patients' symptoms improved during the treatment period compared with symptoms recorded on Day 0. Results: 63 patients were excluded from the analysis due to lack of symptoms on Day 0 or failure to complete pH-monitoring. The sensitivity of an esomeprazole treatment test in confirming GERD increased during the first days of treatment and stabilized between 79% and 86% after 5 days (both esomeprazole arms). The corresponding figure for the placebo arm was 36%. Specificity was variable (24%-65%) for both active treatment and placebo. Conclusion: A treatment test with esomeprazole 40 mg has a high sensitivity in confirming GERD. Furthermore, the data indicate that 1-week treatment with a once-daily dosage is sufficient to ensure adequate diagnosis.

AB - Background: Symptomatic response to acid inhibition can be used as a guide in diagnosing patients with reflux symptoms. The proton-pump inhibitor (PPI) omeprazole has been used as such a diagnostic tool. Intragastric acid control with esomeprazole is more effective than other PPIs and has the potential to offer an advance in the diagnostic use of PPIs. Methods: Patients experiencing heartburn (for ≥6 months) were studied in this randomized, double-blind, multicenter study. Following a 3-day placebo run-in, 440 patients were randomized to 14 days' treatment with esomeprazole 40 mg once daily (o.d.), esomeprazole 20 mg twice daily (b.i.d.) or placebo. Heartburn symptoms were recorded daily. Endoscopy and 24-h esophageal pH-monitoring were performed to determine the presence of gastroesophageal reflux disease (GERD). The esomeprazole treatment test was considered positive if patients' symptoms improved during the treatment period compared with symptoms recorded on Day 0. Results: 63 patients were excluded from the analysis due to lack of symptoms on Day 0 or failure to complete pH-monitoring. The sensitivity of an esomeprazole treatment test in confirming GERD increased during the first days of treatment and stabilized between 79% and 86% after 5 days (both esomeprazole arms). The corresponding figure for the placebo arm was 36%. Specificity was variable (24%-65%) for both active treatment and placebo. Conclusion: A treatment test with esomeprazole 40 mg has a high sensitivity in confirming GERD. Furthermore, the data indicate that 1-week treatment with a once-daily dosage is sufficient to ensure adequate diagnosis.

KW - Diagnostic

KW - Esomeprazole

KW - Gastroesophageal reflux disease

KW - Sensitivity

UR - http://www.scopus.com/inward/record.url?scp=0038147243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038147243&partnerID=8YFLogxK

U2 - 10.1080/00365520310002139

DO - 10.1080/00365520310002139

M3 - Article

C2 - 12739706

AN - SCOPUS:0038147243

VL - 38

SP - 354

EP - 359

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 4

ER -